HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells.

Abstract
KRN5500, (6-[4-Deoxy-4-(2E,4E)-tetradecadienoylglycyl]amino-L-glycero - beta-L-mannoheptopyranosyl]amino-9H-purine), was semi-synthesized in an attempt to increase the therapeutic effects of spicamycin analogues. The present study evaluated the antitumor activity of KRN5500 against murine tumors and human tumor xenografts. KRN5500 prolonged the survival of P388 leukemia- and B16 melanoma-bearing mice but was marginally effective on colon adenocarcinoma 26. The antitumor activity of KRN5500 (4 mg/kg/day x 5, IV) against xenografts of 10 human stomach, 14 colon and 2 esophageal cancers was evaluated with two parameters: the tumor growth inhibition rate (TGIR) and the tumor mass reduction by comparison with mitomycin C (MMC, 6.7 mg/kg/day x 1,IV). KRN5500 showed a marked efficacy in the human tumor xenograft model. The overall response rate of 26 cancers to KRN5500, evaluated by TGIR, was approximately equal to their response rate to MMC (72% vs. 73%). However, more tumors were reduced by KRN5500 than by MMC (52% vs. 39%). It is notable that the response rates of 14 colon cancers to KRN5500 were significantly higher than those to MMC, both in TGIR (69% vs. 58%) and in tumor mass reduction (46% vs. 23%). Among the tumors sensitive to KRN5500, COL-1 showed a marked response (TGIR 93%) and a significant reduction in tumor mass (0.22-fold the starting volume). In the mode of action, KRN5500 was found to show an inhibitory effect on protein synthesis in P388 cells (IC50 1.5 microM). However, KRN5500 was ineffective even at 170 microM in inhibition of protein synthesis in rabbit reticulocyte lysates.(ABSTRACT TRUNCATED AT 250 WORDS)
AuthorsM Kamishohara, H Kawai, T Sakai, T Isoe, K Hasegawa, J Mochizuki, T Uchida, S Kataoka, H Yamaki, T Tsuruo
JournalOncology research (Oncol Res) Vol. 6 Issue 8 Pg. 383-90 ( 1994) ISSN: 0965-0407 [Print] United States
PMID7894087 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Protein Synthesis Inhibitors
  • Purine Nucleosides
  • Mitomycin
  • KRN 5500
Topics
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Female
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred DBA
  • Mice, Inbred Strains
  • Mice, Nude
  • Mitomycin (pharmacology)
  • Neoplasms, Experimental (drug therapy)
  • Protein Synthesis Inhibitors (pharmacology)
  • Purine Nucleosides (antagonists & inhibitors, metabolism, pharmacology)
  • Subrenal Capsule Assay

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: